시장보고서

상품코드

1800921

비흑색종 피부암 치료 시장 보고서 : 치료 유형별, 적응증별, 최종 용도별, 지역별(2025-2033년)

Non-Melanoma Skin Cancer Treatment Market Report by Treatment Type, Indication, End Use, and Region 2025-2033

발행일: 2025년 08월 | 리서치사:

IMARC | 페이지 정보: 영문 145 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

비흑색종 피부암 치료 세계 시장 규모는 2024년 5억 8,880만 달러에 달했습니다. IMARC Group은 이 시장이 2033년까지 8억 7,800만 달러에 달하고, 2025-2033년 4.31%의 연평균 성장률(CAGR)을 보일 것으로 예측했습니다.

비흑색종 피부암(NMSC)은 피부 상층부의 악성 세포가 비정상적으로 증식하는 것을 말합니다. NMSC의 일반적인 유형으로는 기저세포암, 메르켈세포암, 편평상피암, 피부 T세포 림프종 등이 있습니다. 피부에 딱딱한 덩어리나 비늘 모양의 반점이 생기는 것이 주요 특징입니다. 치료 방법으로는 현미경 수술, 레이저 치료, 냉동요법 등 외과적 시술을 통한 암세포 제거와 광역학 치료(PDT), 방사선 치료, 전기치료 등 다양한 비수술적 치료법이 있습니다.

피부암 유병률 증가와 전 세계 노인 인구 증가는 시장 성장을 가속하는 주요 요인으로 작용하고 있습니다. 또한, NMSC의 치료법에 대한 대중의 인식이 높아지면서 시장 성장을 가속하고 있습니다. 기존 치료법에 비해 표재성 방사선 치료는 환자의 신체에 미치는 부작용이 적고, 혁신적인 휴대용 기기를 통해 시행할 수 있습니다. 또한, 이 장비들은 높은 정확도와 민감도로 피부 병변의 조기 진단에도 사용되고 있습니다. 또한, 전자식 브라키테라피(eBx)의 개발 등 다양한 기술 발전도 성장을 가속하는 요인으로 작용하고 있습니다. eBx는 통증이 없는 비침습적 표적 저에너지 방사선 치료로, 치료 기간이 짧고 주변 건강한 조직에 대한 방사선 피폭 위험을 최소화할 수 있습니다. 기타 요인으로는 개인 의료비 지출 증가, 임상시험에 대한 정부 자금 지원, 광범위한 조사 개발(R&D) 활동이 시장을 더욱 견인할 것으로 예측됩니다.

본 보고서에서 다룬 주요 질문

세계 비흑색종 피부암 치료제 시장은 지금까지 어떻게 변화해왔고, 앞으로 어떻게 변화할 것인가?
코로나19가 전 세계 비흑색종 피부암 치료 시장에 미치는 영향은?
주요 지역 시장은?
치료 유형별 시장 분석은?
적응증별 시장 현황은?
최종 용도별 시장 분석은?
산업 가치사슬의 다양한 단계는?
업계의 주요 촉진요인과 과제는?
세계 비흑색종 피부암 치료 시장의 구조와 주요 기업은?
업계 경쟁은 어느 정도인가?

시장 구조
주요 기업
주요 기업 개요
- Accuray Incorporated
- Almirall S.A.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Elekta AB
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Icad Inc.
- Merck & Co. Inc.
- Novartis AG
- Sun Pharmaceutical Industries Limited
- Varian Medical Systems Inc.

LSH 25.09.05

The global non-melanoma skin cancer treatment market size reached USD 588.8 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 878.0 Million by 2033, exhibiting a growth rate (CAGR) of 4.31% during 2025-2033.

Non-melanoma skin cancer (NMSC) refers to the abnormal growth of malignant cells in the upper layer of the skin. Some of the common types of NMSC include basal cell, merkle cell and squamous cell carcinoma and cutaneous T-cell lymphoma. It is primarily characterized by the development of firm lumps or scaly patches on the skin. The treatment methodologies involve the removal of cancer cells through surgical procedures, including micrographic surgery, laser therapy and cryotherapy, and various non-surgical treatments, such as photodynamic therapy (PDT), radiotherapy and electrotherapy.

The increasing prevalence of skin cancer and the rising geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, rising awareness among the masses regarding the available treatment alternatives for NMSC is also stimulating the market growth. In comparison to the traditionally used therapies, superficial radiation therapy has reduced side-effects on the patient's body and can be conducted through innovative portable devices. These devices are also used for early diagnosis of skin lesions with high accuracy and sensitivity. Additionally, various technological advancements, such as the development of electronic brachytherapy (eBx), are acting as other growth-inducing factors. eBx is a painless and non-invasive targeted low-energy radiation therapy that requires a shorter treatment course and minimizes the risks of radiation exposure to the nearby healthy tissues. Other factors, including rising healthcare expenditures of individuals and government funding for clinical trials, along with extensive research and development (R&D) activities, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Treatment Type:

Chemotherapy
Radiation Therapy
Photodynamic Therapy
Others

Breakup by Indication:

Basal Cell Carcinoma
T-Cell Lymphoma
Squamous Cell Carcinoma
Others

Breakup by End Use:

Hospitals
Specialty Clinics
Ambulatory Surgery Centers
Others

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, Icad Inc., Merck & Co. Inc., Novartis AG, Sun Pharmaceutical Industries Limited and Varian Medical Systems Inc.

Key Questions Answered in This Report:

How has the global non-melanoma skin cancer treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global non-melanoma skin cancer treatment market?
What are the key regional markets?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the end use?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global non-melanoma skin cancer treatment market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Non-Melanoma Skin Cancer Treatment Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Treatment Type

6.1 Chemotherapy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Radiation Therapy
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Photodynamic Therapy
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Indication

7.1 Basal Cell Carcinoma
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 T-Cell Lymphoma
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Squamous Cell Carcinoma
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by End Use

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Specialty Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Ambulatory Surgery Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Accuray Incorporated
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Almirall S.A.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Boehringer Ingelheim GmbH
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 SWOT Analysis
- 14.3.4 Bristol-Myers Squibb Company
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 Elekta AB
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Eli Lilly and Company
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 F. Hoffmann-La Roche AG
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 SWOT Analysis
- 14.3.8 Icad Inc.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Merck & Co. Inc.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Novartis AG
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis
- 14.3.11 Sun Pharmaceutical Industries Limited
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
  - 14.3.11.4 SWOT Analysis
- 14.3.12 Varian Medical Systems Inc.
  - 14.3.12.1 Company Overview
  - 14.3.12.2 Product Portfolio
  - 14.3.12.3 Financials
  - 14.3.12.4 SWOT Analysis

비흑색종 피부암 치료 시장 보고서 : 치료 유형별, 적응증별, 최종 용도별, 지역별(2025-2033년)

Non-Melanoma Skin Cancer Treatment Market Report by Treatment Type, Indication, End Use, and Region 2025-2033

본 보고서에서 다룬 주요 질문

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 서론

제5장 세계의 비흑색종 피부암 치료 시장

제6장 시장 분석 : 치료 유형별

제7장 시장 분석 : 적응증별

제8장 시장 분석 : 최종 용도별

제9장 시장 분석 : 지역별

제10장 SWOT 분석

제11장 밸류체인 분석

제12장 Porter의 Five Forces 분석

제13장 가격 분석

제14장 경쟁 구도